Intensity Therapeutics, Inc. is a late-stage clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anticancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct components: one part is soluble in water and the other is soluble in fat or oils. When an amphiphilic compound is mixed with therapeutic agents, such as chemotherapies, the agents also become soluble in both fat and water.
Our lead product candidate, INT230-6, consists of two proven anticancer cytotoxic agents, cisplatin and vinblastine, mixed with the amphiphilic molecule (SHAO) — all in one vial. In June 2024, we initiated a Phase 3 clinical trial in metastatic sarcoma, the INVINCIBLE-3 study. Phase three study will test our drug compared to the standard of care in second and third line treatment. We also plan to initiate a Phase 2/3 program testing our drug with and without the standard of care neoadjuvant therapy in women with triple negative breast cancer. Prior to these two late stage studies we completed two studies; the first study was a phase 1/2 dose escalation study in patients with refractory metastatic cancer. The second study was a randomized window of opportunity study that tested our drug in women who, after diagnosis, must wait until the surgery. More information about all our clinical trials may be found on our clinical research page.